Ryujin
This study was pointed toward giving a few experiences into the genuine presentation of the business, clinically approved enemy of SARS-CoV-2 immunizer examines. The leftover, anonymized tests from 97 patients alluded for against SARS-CoV-2 antibodies testing were remembered for the review. The underlying evaluation was performed with the Euroimmun ELISAs, trailed by the examines gave by: NovaTec, Snibe, Vircell, Roche, Abbott and DiaSorin. The investigations of the outcomes were performed independently for the antibodies of the early (IgM/IgA) and late (IgG) invulnerable reaction.
இந்தக் கட்டுரையைப் பகிரவும்
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 